Selective growth inhibition of cancer cells with doxorubicin-loaded CB[7]-modified iron-oxide nanoparticles

UDC.coleccionInvestigaciónes_ES
UDC.departamentoQuímicaes_ES
UDC.endPage23834es_ES
UDC.grupoInvReactividade Química e Fotorreactividade (REACT!)es_ES
UDC.issue38es_ES
UDC.journalTitleRSC Advanceses_ES
UDC.startPage23827es_ES
UDC.volume7es_ES
dc.contributor.authorBenyettou, Farah
dc.contributor.authorFahs, H.
dc.contributor.authorElkharrag, R.
dc.contributor.authorBilbeisi, Rana A.
dc.contributor.authorAsmaa, Bouakaz
dc.contributor.authorRezgui, Rachid
dc.contributor.authorMotte, Laurence
dc.contributor.authorMagzoub, Mazin
dc.contributor.authorBrandel, J.
dc.contributor.authorOlsen, John-Carl
dc.contributor.authorPiano, F.
dc.contributor.authorGunsalus, K. C.
dc.contributor.authorPlatas-Iglesias, Carlos
dc.contributor.authorTrabolsi, Ali
dc.date.accessioned2019-11-05T13:53:48Z
dc.date.available2019-11-05T13:53:48Z
dc.date.issued2017-05-03
dc.description.abstract[Abstract] Cucurbit[7]uril-modified iron-oxide nanoparticles (CB[7]NPs) were loaded with doxorubicin hydrochloride (Dox) and tested as a drug delivery system. Dox was found to interact with the carbonyl-rich rims of the CB[7] macrocycles adsorbed on the surface of the nanoparticles. The Dox-loaded nanoparticles (Dox@CB[7]NPs) were stable at room temperature and physiological pH and released their Dox cargo under acidic conditions, in the presence of glutathione, or with heating. Dox@CB[7]NPs reduced the viability of HeLa and three other cancer-derived cell lines in vitro at lower IC50 than free Dox. They were also nontoxic to C. elegans. The sensitivity of HeLa cells to Dox@CB[7]NPs was enhanced when the temperature was elevated by application of an alternating magnetic field. Thus, Dox@CB[7]NPs show promise as agents for the intracellular delivery of Dox to cancer cells, for the selective and controlled release of the drug, and, more generally, as a possible means of combining chemotherapeutic and hyperthermic treatment modalities.es_ES
dc.description.sponsorshipAl Jalila Foundation; AJF 201425es_ES
dc.description.sponsorshipAl Jalila Foundation; AJF 201538es_ES
dc.identifier.citation1 F. Benyettou, H. Fahs, R. Elkharrag, R. A. Bilbeisi, B. Asma, R. Rezgui, L. Motte, M. Magzoub, J. Brandel, J. C. Olsen, F. Piano, K. C. Gunsalus, C. Platas-Iglesias and A. Trabolsi, RSC Adv., 2017, 7, 23827–23834.es_ES
dc.identifier.issn2046-2069
dc.identifier.urihttp://hdl.handle.net/2183/24243
dc.language.isoenges_ES
dc.publisherRoyal Society of Chemistryes_ES
dc.relation.urihttp://doi.org/10.1039/C7RA02693Ees_ES
dc.rightsAtribución 3.0 Españaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/es/*
dc.subjectIron oxidees_ES
dc.subjectDoxorubicines_ES
dc.subjectCurcubit[7]uriles_ES
dc.subjectCanceres_ES
dc.subjectHyperthermiaes_ES
dc.titleSelective growth inhibition of cancer cells with doxorubicin-loaded CB[7]-modified iron-oxide nanoparticleses_ES
dc.typejournal articlees_ES
dspace.entity.typePublication
relation.isAuthorOfPublication8bb35ae5-5c53-4d41-87b8-949a82445202
relation.isAuthorOfPublication.latestForDiscovery8bb35ae5-5c53-4d41-87b8-949a82445202

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PlatasIglesias_Carlos_2017_Selective_growth_inhibition_cancer_cell_doxorubicin-loaded_CB[7]-modified_iron-oxide_nanoparticles.pdf
Size:
772.64 KB
Format:
Adobe Portable Document Format
Description: